Lionheart Health, Inc., a biotechnology company specializing in bioelectric regeneration and longevity, announced the filing of a non-provisional U.S. patent for its Bioelectric-Enhanced Klotho Nanoflowers platform. The technology integrates nanoflower-shaped nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to address the cellular and mitochondrial drivers of aging.
The patented system incorporates multiple proprietary technologies, including BodStim™, BrainBand™, HairCell™, and advanced Klotho-based peptides and gene-expression tools. The nanoflowers are engineered to upregulate Klotho, a longevity-associated protein linked to improved brain, kidney, cardiovascular, and metabolic health. They also restore mitochondrial function by enhancing ATP production and reducing oxidative stress, deliver targeted bioactive agents such as peptides and mRNA, and act as nanozyme catalysts to reduce reactive oxygen species.
According to Howard J. Leonhardt, Founder and CEO of Lionheart Health, the invention represents the convergence of bioelectric signaling, nanomedicine, and Klotho modulation. The nanoflowers are designed to respond to proprietary bioelectric stimulation sequences, which increase cellular uptake and activate intracellular pathways. The bioelectric signals open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release. Klotho expression is enhanced through both nanoflower-delivered genetic payloads and bioelectric activation of promoter and epigenetic pathways, creating a combined therapeutic benefit.
The platform aims for system-wide healthspan improvement, including mitochondrial biogenesis via activation of PGC-1α, NRF1/2, and TFAM, reduction of cellular senescence by lowering oxidative stress, and stabilization of biological age through combined mitochondrial repair and Klotho enhancement. Klotho is recognized as a promising longevity molecule, with decreased levels associated with accelerated aging, cognitive decline, and frailty.
Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, stated that the platform provides a programmable, multi-modal tool to address root causes of aging such as declining energy production, rising inflammation, and loss of regenerative capacity. The patent filing adds to Lionheart Health’s intellectual property portfolio, which includes bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and Klotho-based gene therapy.
Optional components of the platform include closed-loop adaptive control using sensors to measure mitochondrial markers, multi-modal integration with red light and PEMF, and repeat cycle integration for iterative therapy sessions. Lionheart Health is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program. More information is available at LionheartHealthStim.com and LionheartLongevity.com.
